Serum SARS-CoV-2 Neutralization Activity

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    -99
  • Known Financial Commitments (USD)

    $0
  • Funder

    University of Minnesota
  • Principal Investigator

    MD. Tyler Bold
  • Research Location

    United States of America
  • Lead Research Institution

    Medical School, University of Minnesota
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The U.S. government has tasked America's universities to develop assays that detect anti-SARS-CoV-2 antibodies in the blood. These tests can define the scope of a population's exposure to SARS-CoV-2 virus, and also identify individuals who may have protective immunity against re-infection. Those with anti-viral antibodies can also donate potentially protective convalescent plasma/serum. "To fully interpret the results of antibody tests, we need a better understanding of whether the antibodies induced by COVID-19 will confer immune protection against subsequent infection with SARS-CoV-2," said Tyler Bold, MD, PhD, assistant professor, Department of Medicine, who is leading this study. "We will use our existing expertise working with BSL3 pathogens to develop a SARS-CoV-2 live viral neutralization assay, that can be used to quantitatively test sera for anti-viral neutralization activity."